Literature DB >> 24352633

Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt.

Sabrina De Winter1, Sandra Verelst, Joost Wauters, Lorenz Van der Linden, Chris Verslype, Ludo Willems, Isabel Spriet.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24352633     DOI： 10.1007/s00228-013-1629-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  4 in total

Review 1.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.

Authors:  N Chalasani; J C Gorski; N H Patel; S D Hall; R E Galinsky
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 3.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

4.  The impact of a transjugular intrahepatic portosystemic shunt on the pharmacokinetics of caspofungin in a critically ill patient.

Authors:  Isabel Spriet; Geert Meyfroidt; Geert Maleux; Chris Verslype; Ludo Willems
Journal:  Pharmacology       Date:  2012-09-20       Impact factor: 2.547
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.